Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Gene Therapy
|
April 23, 2010
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor
T J Harvey, D Burdon, L Steele, et al.
British Journal of Cancer
|
August 12, 2004
Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study
G D Hall, J M Brown, R E Coleman, et al.
British Journal of Cancer
|
April 21, 2011
ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival
A Brüning-Richardson, J Bond, R Alsiary, et al.
International Journal of Cancer
|
August 29, 2013
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
V A Jennings, E J Ilett, K J Scott, et al.
British Journal of Urology
|
May 1, 1996
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation
J K Joffe, R E Banks, M A Forbes, et al.
British Journal of Cancer
|
March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
R M Glasspool, R Brown, M E Gore, et al.
British Journal of Cancer
|
March 31, 2017
Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium
T Goranova, D Ennis, A M Piskorz, et al.
British Journal of Cancer
|
March 14, 2019
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium
T Goranova, D Ennis, A M Piskorz, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Gene Therapy
|
April 23, 2010
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor
T J Harvey, D Burdon, L Steele, et al.
British Journal of Cancer
|
August 12, 2004
Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study
G D Hall, J M Brown, R E Coleman, et al.
British Journal of Cancer
|
April 21, 2011
ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival
A Brüning-Richardson, J Bond, R Alsiary, et al.
International Journal of Cancer
|
August 29, 2013
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
V A Jennings, E J Ilett, K J Scott, et al.
British Journal of Urology
|
May 1, 1996
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation
J K Joffe, R E Banks, M A Forbes, et al.
British Journal of Cancer
|
March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
R M Glasspool, R Brown, M E Gore, et al.
British Journal of Cancer
|
March 31, 2017
Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium
T Goranova, D Ennis, A M Piskorz, et al.
British Journal of Cancer
|
March 14, 2019
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium
T Goranova, D Ennis, A M Piskorz, et al.
Page
of 3